AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30217227 — intervention group
Group type: EXPERIMENTAL
Intervention: modified TSFE with bone grafting
Number of subjects: 120
Study 30217227 — intervention group
Group type: EXPERIMENTAL
Intervention: modified TSFE without bone grafting
Number of subjects: 120
Study 30217228 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate injection
Number of subjects: 0
Study 30217228 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 30217377 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-enabled home-based cardiac rehabilitation program
Number of subjects: 18
Study 30217421 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 ESC Guidelines Class I indication (538 patients)
Number of subjects: 930
Study 30217421 — intervention group
Group type: COMPARATOR
Intervention: 2013 ESC Guidelines Class I indication (650 patients)
Number of subjects: 930
Study 30217536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (2 ng/kg body weight)
Number of subjects: 22
Study 30217536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction error signal (discrepancy between immune signal and sickness expectancy)
Number of subjects: 22
Study 30217579 — intervention group
Group type: EXPERIMENTAL
Intervention: Established obstructive sleep apnea screening tools
Number of subjects: 0
Study 30217579 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sleep apnea testing
Number of subjects: 0
Study 30217579 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, body mass index, neck circumference, frequently witnessed apneas, and highly likely to fall asleep while driving
Number of subjects: 0
Study 30217671 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin and olaparib combination treatment
Number of subjects: 50
Study 30218434 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 517
Study 30218434 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 517
Study 30218651 — intervention group
Group type: EXPERIMENTAL
Intervention: Optogenetic approaches to vision restoration
Number of subjects: 0
Study 30218977 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3039478 50mg/75mg three times per week for 28-day cycle until disease progression
Number of subjects: 69
Study 30218977 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3039478
Number of subjects: 69
Study 30219086 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 290
Study 30219086 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (AC)
Number of subjects: 290
Study 30219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocryosurgery (5% imiquimod cream daily for five weeks and cryosurgery on day fourteen)
Number of subjects: 55
Study 30219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat immunocryosurgery cycles
Number of subjects: 55
Study 30219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine in pregnant women
Number of subjects: 599
Study 30219367 — intervention group
Group type: COMPARATOR
Intervention: Tdap vaccine in nonpregnant women
Number of subjects: 599
Study 30219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine in pregnant women and nonpregnant women
Number of subjects: 599
Study 30219500 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) using Computer Assisted Sensation Evaluator IVc (CASE IVc)
Number of subjects: 169
Study 30219500 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Somatotopic Quantitative Sensation Testing (S ST QSTing)
Number of subjects: 169
Study 30219628 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib plus binimetinib
Number of subjects: 577
Study 30219628 — intervention group
Group type: COMPARATOR
Intervention: vemurafenib
Number of subjects: 577
Study 30219628 — intervention group
Group type: COMPARATOR
Intervention: encorafenib
Number of subjects: 577
Study 30219763 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 57
Study 30219763 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcalorimetry
Number of subjects: 57
Study 30219763 — intervention group
Group type: COMPARATOR
Intervention: SF Culture
Number of subjects: 57
Study 30219791 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous sinus stenting (VSS)
Number of subjects: 70
Study 30219793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=306) booked for IUD insertion 1-4 weeks after MTOP at the hospital.
Number of subjects: 605
Study 30219793 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=299) advised to contact their primary healthcare (PHC) centre for follow-up and IUD insertion.
Number of subjects: 605
Study 30219793 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=299) for IUD insertion within 3 months.
Number of subjects: 605
Study 30219858 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine treatment
Number of subjects: 18
Study 30219858 — intervention group
Group type: COMPARATOR
Intervention: no l-carnitine treatment
Number of subjects: 18
Study 30219915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab i.v. every 3 weeks for 16 cycles, up to 1 year or until loss of clinical benefit.
Number of subjects: 32
Study 30219920 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 22311
Study 30219937 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of quality of life (QOL) using the Medical Outcome Study-HIV Survey (MOS-HIV)
Number of subjects: 223
Study 30219937 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates' assessment of patients' quality of life (QOL) using the Palliative care Outcome Scale (POS)
Number of subjects: 223
Study 30219937 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared HIV diagnosis between patient and surrogate
Number of subjects: 223
Study 30220300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiband mucosectomy (MBM) device
Number of subjects: 291
Study 30220708 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus and pazopanib (E/P)
Number of subjects: 19
Study 30221011 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and sildenafil (100 mg by mouth daily during therapy, three times daily on the day of doxorubicin)
Number of subjects: 27
Study 30221011 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin chemotherapy alone
Number of subjects: 27
Study 30221150 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg EOW
Number of subjects: 28
Study 30221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor injuries
Number of subjects: 1191
Study 30221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate injuries
Number of subjects: 1191
Study 30221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe injuries
Number of subjects: 1191
Study 30221344 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 1191
Study 30221827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg every 8 hours, adjusted for CrCL ≤ 50 mL/min)
Number of subjects: 0
Study 30221827 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 30222141 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 63
Study 30222141 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 63
Study 30222972 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided photodynamic therapy (PDT) with intravenous porfimer sodium followed by EUS-PDT
Number of subjects: 12
Study 30223771 — intervention group
Group type: EXPERIMENTAL
Intervention: DelApp smartphone application for assessing inattention in delirium, administered within 3 hours of reference standard assessment.
Number of subjects: 500
Study 30223779 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote health coach intervention
Number of subjects: 30
Study 30223802 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based exclusion of the non-tumor-bearing parts of the uterus from the target volume
Number of subjects: 0
Study 30223870 — intervention group
Group type: EXPERIMENTAL
Intervention: Family centered Function-focused Care
Number of subjects: 438
Study 30223870 — intervention group
Group type: COMPARATOR
Intervention: Education-only (Control)
Number of subjects: 438
Study 30223874 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) with demonstrations, kit distribution, and private spaces for use
Number of subjects: 15
Study 30223874 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard of care (optimized PITC with additional training, job aids, and monitoring)
Number of subjects: 15
Study 30223874 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (routine provider-initiated testing and counseling)
Number of subjects: 15
Study 30223874 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 15
Study 30223877 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 192
Study 30224031 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS score
Number of subjects: 1490
Study 30224031 — intervention group
Group type: COMPARATOR
Intervention: Nine scores
Number of subjects: 1490
Study 30224193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (15 mg single oral dose)
Number of subjects: 16
Study 30224284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, pioglitazone, and lifestyle therapy
Number of subjects: 422
Study 30224284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, pioglitazone, GLP-1 receptor agonist, and lifestyle therapy
Number of subjects: 422
Study 30224284 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy only
Number of subjects: 422
Study 30224303 — intervention group
Group type: EXPERIMENTAL
Intervention: iNEWS score (infant early nutrition warning score)
Number of subjects: 42
Study 30224303 — intervention group
Group type: EXPERIMENTAL
Intervention: High iNEWS score
Number of subjects: 42
Study 30224303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic assessment
Number of subjects: 42
Study 30224322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 22803
Study 30224322 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blocking agents
Number of subjects: 22803
Study 30224333 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbr mobile phone app suite including daily visual self-reports, rehabilitation video tutorials, passive activity-level measurement, and chat-based health coaching.
Number of subjects: 93
Study 30224333 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Activities of Daily Living module
Number of subjects: 93
Study 30224340 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-labeled bone marrow cell transplants (injected with ferumoxytol nanoparticles)
Number of subjects: 7
Study 30224340 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled cell transplants (control group)
Number of subjects: 7
Study 30224389 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of patients and their primary informal caregivers every 4 months until patients' death; caregivers followed until 8 weeks postpatient death.
Number of subjects: 250
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets prescribed
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for musculoskeletal pain
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for fracture
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for renal colic or abdominal pain
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for other pain conditions
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for first 3 days
Number of subjects: 627
Study 30224393 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall opioid consumption
Number of subjects: 627
Study 30224926 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine ICH-012 (8 herbal medicines including Hirudo and Tabanus)
Number of subjects: 0
Study 30224926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 0
Study 30224926 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine ICH-012
Number of subjects: 0
Study 30225601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with gemcitabine (GEM) 1000 mg/m² for three cycles followed by gemcitabine-erlotinib and radiotherapy
Number of subjects: 25
Study 30225844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral immunotherapy (OIT) with biweekly dose step-up until reaching maximum maintenance dose (MMD) of 5000 mg peanut protein or individual maintenance dose (IMD).
Number of subjects: 77
Study 30225844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral immunotherapy (OIT)
Number of subjects: 77
Study 30225844 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (observation only control group)
Number of subjects: 77
Study 30225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 137
Study 30225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF withdrawal
Number of subjects: 137
Study 30225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum S100A8/A9 levels
Number of subjects: 137
Study 30225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum S100A12 levels
Number of subjects: 137
Study 30226851 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 847
Study 30227072 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-551, an anti-CD 19 B-cell depleting monoclonal antibody, administered for up to 197 days
Number of subjects: 0
Study 30227072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30227108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 0
Study 30227108 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30227144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diasorin Liaison platform assay
Number of subjects: 219
Study 30227144 — intervention group
Group type: COMPARATOR
Intervention: LC-MS/MS method
Number of subjects: 219
Study 30227144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diasorin and Roche automated assays
Number of subjects: 219
Study 30227169 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217
Study 30227169 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study 30227842 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual optimal diets developed through linear programming
Number of subjects: 576
Study 30227842 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear programming dietary modeling
Number of subjects: 576
Study 30227842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modeling
Number of subjects: 576
Study 30227842 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means cluster analysis of optimized diets
Number of subjects: 576
Study 30227856 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy at month 3
Number of subjects: 0
Study 30227856 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy at month 1
Number of subjects: 0
Study 30227856 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy at baseline
Number of subjects: 0
Study 30227856 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors (headaches, psychological symptoms, arterial hypertension, EuroQol visual analog scale)
Number of subjects: 0
Study 30227856 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up variables (Epworth and average nighttime hours)
Number of subjects: 0
Study 30227864 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS plus finger tracking training
Number of subjects: 6
Study 30227886 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg tremelimumab at 90 day intervals
Number of subjects: 360
Study 30227893 — intervention group
Group type: EXPERIMENTAL
Intervention: brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, IL-15 agonist, IDO1 inhibitor
Number of subjects: 0
Study 30227964 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic AF patients
Number of subjects: 9319
Study 30227964 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic AF patients
Number of subjects: 9319
Study 30228248 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 2797
Study 30228251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffless PTT device (TestBP)
Number of subjects: 71
Study 30228251 — intervention group
Group type: COMPARATOR
Intervention: Cuff-based standard BP device (RefBP)
Number of subjects: 71
Study 30228904 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of clarithromycin treatment
Number of subjects: 2199
Study 30228904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study 30229280 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46, with increased dose of 1.5 mg/kg for inadequate response from week 14 to week 46.
Number of subjects: 12
Study 30229280 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 treatment
Number of subjects: 12
Study 30230252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programs
Number of subjects: 1150
Study 30230252 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1150
Study 30230263 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled batefenterol
Number of subjects: 0
Study 30230947 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster dose in children
Number of subjects: 2
Study 30230947 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV single dose primary vaccination in toddlers
Number of subjects: 2
Study 30231626 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 9
Study 30231626 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 9
Study 30231626 — intervention group
Group type: COMPARATOR
Intervention: topiramate
Number of subjects: 9
Study 30231626 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 9
Study 30231626 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 9
Study 30231665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg [14C]-MT-1303
Number of subjects: 0
Study 30231851 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (switch from cyclosporine)
Number of subjects: 797
Study 30231851 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (standard regimen)
Number of subjects: 797
Study 30231851 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure cyclosporine
Number of subjects: 797
Study 30231851 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 797
Study 30231851 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI therapy
Number of subjects: 797
Study 30231854 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and CTC assessments during radiation therapy
Number of subjects: 0
Study 30231854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CTCs and MRI
Number of subjects: 0
Study 30231854 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of MR imaging and CTC assessments
Number of subjects: 0
Study 30231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg every 4 weeks, with additional doses on days 8 and 15 of cycle 1.
Number of subjects: 100
Study 30231899 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment
Number of subjects: 0
Study 30231899 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30231923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with T2DM
Number of subjects: 111
Study 30232114 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated condition (visual information provided prior to jump)
Number of subjects: 70
Study 30232114 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanticipated condition (visual information provided 400 msec prior to landing)
Number of subjects: 70
Study 30232114 — intervention group
Group type: COMPARATOR
Intervention: ACL-reconstructed individuals
Number of subjects: 70
Study 30232114 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 70
Study 30232146 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003
Number of subjects: 0
Study 30232146 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30232224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg twice daily for 7 days every 21 days
Number of subjects: 60
Study 30232415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabone single UCB transplant
Number of subjects: 23
Study 30232558 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally once daily until disease progression or unacceptable toxicity
Number of subjects: 25
Study 30232587 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT Roadmap
Number of subjects: 39
Study 30232616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative probe-based confocal laser endomicroscopy (pCLE) with near-infrared illumination and indocyanine green as contrast agent.
Number of subjects: 21
Study 30232735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 248
Study 30232735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 248
Study 30233062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation using subjects' own name
Number of subjects: 14
Study 30233062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation using music and noise
Number of subjects: 14
Study 30233062 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study 30233062 — intervention group
Group type: EXPERIMENTAL
Intervention: QEEG index in specific stimulation states
Number of subjects: 14